Our docking studies determined that among the FDA-approved compounds, enasidenib and gilteritinib exhibited the best binding interaction with ALDH1A1 and CFD, respectively; thus, they are the best therapeutic compounds for AML treatment. This evidence concerns the gene ALDH1A1 and acute myeloid leukemia.